Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MXCT

MaxCyte Inc

Apr 19 • 03:48PM ET

3.93

Dollar change +0.05
Percentage change 1.42	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO VHT DFAC IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.37	Insider Own	12.22%	Shs Outstand	103.96M	Perf Week	-1.63%
Market Cap	409.75M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-1.39%	Shs Float	91.41M	Perf Month	-12.56%
Income	-37.92M	PEG	-	EPS next Q	-0.12	Inst Own	71.03%	Short Float	3.56%	Perf Quarter	-23.14%
Sales	41.29M	P/S	9.92	EPS this Y	-32.82%	Inst Trans	0.19%	Short Ratio	5.47	Perf Half Y	23.35%
Book/sh	2.23	P/B	1.76	EPS next Y	16.23%	ROA	-13.67%	Short Interest	3.26M	Perf Year	-22.08%
Cash/sh	1.62	P/C	2.43	EPS next 5Y	-	ROE	-15.60%	52W Range	2.45 - 5.55	Perf YTD	-16.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.20%	ROI	-15.16%	52W High	-29.04%	Beta	-
Dividend TTM	-	Quick Ratio	9.97	Sales past 5Y	20.83%	Gross Margin	78.86%	52W Low	60.61%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	10.65	EPS Y/Y TTM	-58.43%	Oper. Margin	-116.74%	RSI (14)	39.16	Volatility	3.88% 3.85%
Employees	143	Debt/Eq	0.08	Sales Y/Y TTM	-6.71%	Profit Margin	-91.84%	Recom	1.00	Target Price	9.33
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-8.07%	Payout	-	Rel Volume	0.65	Prev Close	3.88
Sales Surprise	16.53%	EPS Surprise	26.79%	Sales Q/Q	26.10%	Earnings	May 07 AMC	Avg Volume	595.25K	Price	3.93
SMA20	-5.35%	SMA50	-9.46%	SMA200	-6.03%	Trades		Volume	375,640	Change	1.42%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	Loading…
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire)
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
11:05AM	Loading…
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
04:54AM	Loading…
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-27-23 04:05PM	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer (GlobeNewswire)
Mar-18-23 02:06AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 01:33AM	MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021) (Simply Wall St.)
Mar-15-23 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-08-23 08:00AM	MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology (GlobeNewswire)
Mar-06-23 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance (PR Newswire) -7.55%
Feb-22-23 06:37PM	7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 (InvestorPlace)
Feb-01-23 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-29-23 03:03AM	A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impress (Simply Wall St.)
Jan-03-23 04:05PM	MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs (PR Newswire) -6.23%
Dec-21-22 09:35AM	MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-19-22 12:55PM	7 Hot Stocks to Book Profits In Before 2023 (InvestorPlace)
Dec-16-22 06:42AM	MaxCyte (LON:MXCT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Dec-08-22 12:00PM	MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-05-22 02:00AM	MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases (GlobeNewswire) -10.69%
Nov-19-22 03:18AM	Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m (Simply Wall St.)
Nov-09-22 06:35PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.36%
05:35PM	MaxCyte Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-02-22 08:05AM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-23-22 07:29PM	Should You Invest in MaxCyte (MXCT)? (Insider Monkey)
Oct-20-22 10:16AM	MaxCyte (LON:MXCT) shareholders have earned a 65% CAGR over the last three years (Simply Wall St.)
Oct-18-22 11:38AM	Should You Invest in MaxCyte (MXCT)? (Insider Monkey)
Oct-12-22 08:00AM	MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 (GlobeNewswire)
Sep-28-22 12:39PM	MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders (Benzinga) +7.57%
08:05AM	MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program (GlobeNewswire)
Sep-21-22 09:32AM	Montgomery County biotech MaxCyte unveils new HQ to expand headcount, manufacturing (American City Business Journals)
08:23AM	MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last? (Zacks)
08:05AM	MaxCyte Debuts New State-of-the-Art Headquarters in Marylands I-270 Biotech Corridor (GlobeNewswire)
Sep-13-22 12:30PM	Is it a Good Time to Dispose Your MaxCyte (MXCT) Shares? (Insider Monkey)
Sep-07-22 04:05PM	MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
01:29AM	RGAIA Investment: MacCyte (MXCT) is Uniquely Well Positioned to Benefit (Insider Monkey)
Aug-25-22 11:00AM	RGA Investment Advisors Considers MaxCyte (MXCT)s Business Model To Be High-Quality (Insider Monkey)
Aug-22-22 02:59AM	With 69% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns (Simply Wall St.) -5.87%
Aug-11-22 07:00AM	MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-10-22 05:25PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of MXCT.OQ earnings conference call or presentation 10-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results (PR Newswire)
Jul-15-22 08:00AM	MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022 (GlobeNewswire)
Jul-12-22 08:00AM	MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs (GlobeNewswire)
Jun-23-22 03:50AM	We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth (Simply Wall St.) +11.51%
May-13-22 04:30PM	MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:45AM	MaxCyte (LON:MXCT) pulls back 22% this week, but still delivers shareholders solid 28% CAGR over 3 years (Simply Wall St.)
May-10-22 05:00AM	MaxCyte, Inc. (MXCT) Q1 2022 Earnings Call Transcript (Motley Fool)
May-09-22 04:05PM	MaxCyte Reports First Quarter Financial Results (PR Newswire)
May-03-22 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.34%
Apr-20-22 04:05PM	MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022 (GlobeNewswire)
Apr-15-22 09:00AM	MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-12-22 04:05PM	MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue (GlobeNewswire)
Mar-22-22 11:30PM	MaxCyte, Inc. (MXCT) Q4 2021 Earnings Call Transcript (Motley Fool)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year Financial Results (PR Newswire)
Mar-15-22 03:56AM	Is MaxCyte, Inc. (LON:MXCT) Popular Amongst Institutions? (Simply Wall St.)
Mar-09-22 04:15PM	MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer (GlobeNewswire)
Feb-24-22 08:00AM	MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022 (GlobeNewswire)
Feb-14-22 08:00AM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-11-22 05:00PM	MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-22 02:00AM	MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs (GlobeNewswire)
Jan-24-22 02:30AM	MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results (GlobeNewswire) +5.31%
Jan-14-22 06:53AM	Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation (Simply Wall St.)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnston John Joseph	Director	Mar 26 '24	Option Exercise	2.14	5,000	10,710	125,583	Mar 28 04:31 PM
Johnston John Joseph	Director	Mar 26 '24	Sale	4.41	5,000	22,025	120,583	Mar 28 04:31 PM
Johnston John Joseph	Director	Jan 26 '24	Option Exercise	2.14	5,000	10,710	125,583	Jan 30 04:30 PM
Johnston John Joseph	Director	Jan 26 '24	Sale	5.12	5,000	25,585	120,583	Jan 30 04:30 PM
Johnston John Joseph	Director	Dec 26 '23	Option Exercise	2.14	5,000	10,710	125,583	Dec 28 04:30 PM
Johnston John Joseph	Director	Dec 26 '23	Sale	4.53	5,000	22,650	120,583	Dec 28 04:30 PM
Doerfler Douglas	President and CEO	Dec 05 '23	Option Exercise	0.04	99,442	3,978	432,639	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 05 '23	Sale	5.17	99,442	514,115	333,197	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 04 '23	Option Exercise	0.04	25,008	1,000	358,205	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 04 '23	Sale	5.01	25,008	125,290	333,197	Dec 06 04:15 PM
Doerfler Douglas	President and CEO	Dec 01 '23	Option Exercise	0.04	20,200	808	353,397	Dec 01 05:14 PM
Doerfler Douglas	President and CEO	Dec 01 '23	Sale	5.00	20,200	101,000	333,197	Dec 01 05:14 PM
Doerfler Douglas	President and CEO	Nov 29 '23	Option Exercise	0.04	5,350	214	338,547	Dec 01 05:14 PM
Doerfler Douglas	President and CEO	Nov 29 '23	Sale	5.00	5,350	26,750	333,197	Dec 01 05:14 PM
Johnston John Joseph	Director	Nov 27 '23	Option Exercise	2.14	5,000	10,710	125,583	Nov 29 04:36 PM
Johnston John Joseph	Director	Nov 27 '23	Sale	4.59	5,000	22,950	120,583	Nov 29 04:36 PM
Johnston John Joseph	Director	Nov 14 '23	Option Exercise	1.71	10,000	17,053	130,583	Nov 16 04:48 PM
Johnston John Joseph	Director	Nov 14 '23	Sale	3.71	10,000	37,100	120,583	Nov 16 04:48 PM
Johnston John Joseph	Director	Aug 30 '23	Option Exercise	1.64	2,841	4,662	123,424	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 30 '23	Sale	3.70	2,841	10,512	120,583	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 29 '23	Option Exercise	1.64	2,059	3,379	122,642	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 29 '23	Sale	3.70	2,059	7,618	120,583	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 28 '23	Option Exercise	1.64	100	164	120,683	Aug 30 05:22 PM
Johnston John Joseph	Director	Aug 28 '23	Sale	3.70	100	370	120,583	Aug 30 05:22 PM
Johnston John Joseph	Director	Jul 26 '23	Option Exercise	1.64	5,000	8,205	125,583	Jul 28 04:30 PM
Johnston John Joseph	Director	Jul 26 '23	Sale	4.75	5,000	23,750	120,583	Jul 28 04:30 PM
Doerfler Douglas	President and CEO	Jul 12 '23	Option Exercise	0.04	16,757	670	349,954	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 12 '23	Sale	5.02	16,757	84,120	333,197	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 11 '23	Option Exercise	0.04	12,798	512	345,995	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 11 '23	Sale	5.04	12,798	64,502	333,197	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 10 '23	Option Exercise	0.04	445	18	333,642	Jul 12 06:06 PM
Doerfler Douglas	President and CEO	Jul 10 '23	Sale	5.01	445	2,229	333,197	Jul 12 06:06 PM
Johnston John Joseph	Director	Jun 27 '23	Option Exercise	1.64	7,471	12,260	128,054	Jun 28 05:05 PM
Johnston John Joseph	Director	Jun 27 '23	Sale	4.39	7,471	32,798	120,583	Jun 28 05:05 PM
Johnston John Joseph	Director	Jun 26 '23	Option Exercise	1.05	7,529	7,870	128,112	Jun 28 05:05 PM
Johnston John Joseph	Director	Jun 26 '23	Sale	4.49	7,529	33,805	120,583	Jun 28 05:05 PM
Doerfler Douglas	President and CEO	Jun 14 '23	Option Exercise	0.04	28,883	1,155	362,080	Jun 15 04:30 PM
Doerfler Douglas	President and CEO	Jun 14 '23	Sale	5.04	28,883	145,570	333,197	Jun 15 04:30 PM
Doerfler Douglas	President and CEO	Jun 13 '23	Option Exercise	0.04	14,968	599	348,165	Jun 15 04:30 PM
Doerfler Douglas	President and CEO	Jun 13 '23	Sale	5.03	14,968	75,289	333,197	Jun 15 04:30 PM
Doerfler Douglas	President and CEO	May 03 '23	Option Exercise	0.04	16,149	646	349,346	May 05 05:09 PM
Doerfler Douglas	President and CEO	May 03 '23	Sale	5.02	16,149	81,068	333,197	May 05 05:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MXCT

MaxCyte Inc

Upgrade your FINVIZ experience